SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis
Victor Razuk(Mount Sinai Hospital), Roxana Mehran(Mount Sinai Hospital), Carlo Andrea Pivato(Cardiovascular Institute of the South), David Power(Cardiovascular Institute of the South), Davis Jones(Cardiovascular Institute of the South), George Dangas(Mount Sinai Hospital), Anton Camaj(Columbia University Irving Medical Center), Alessandro Spirito(University of Bern), Johny Nicolas(Cardiovascular Institute of the South), Mauro Chiarito(Humanitas University), Frans Beerkens(Icahn School of Medicine at Mount Sinai), Alvin Mathew(Cardiovascular Institute of the South), Davide Cao(Cardiovascular Institute of the South), Johanna Contreras, Aviv Alter(Elmhurst Hospital Center)
Cited by 41
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k